Search Results
Your search for ,foR matches 32605 pages
Showing 4251 - 4300Vitamin A and Risk for Pancreatitis During Chemotherapy for ALL
Consuming a diet rich in vitamin A or its analogs may help prevent pediatric and young adult patients with acute lymphoblastic leukemia (ALL) reduce their risk of developing pancreatitis during chemotherapy, according to a recent study by Tsai et al in Science Translational Medicine. Background For ...
Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR T-Cell Therapy
Researchers have revealed how microorganisms in the gut may influence the outcomes of patients with non-Hodgkin lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a study published by Stein-Thoeringer et al in Nature Medicine. Background Microorganisms live in or on...
Racial Inequalities in Prostate Cancer Care May Be Associated With Facility-Level Disparities
Racial minorities in the United States may be less likely to receive treatment for prostate cancer and, overall, have worse survival outcomes compared with individuals who are White, according to a new study published by Nguyen et al in Urologic Oncology. Typically, patient-level and...
COVID-19 Vaccination Rates May Be Lower in Patients With Cancer Who Have Comorbidities, Certain Types of Cancer, and Specific Sociodemographic Factors
Investigators have found that patients undergoing treatment for cancer who have comorbidities, metastatic solid or non–B-cell hematologic malignancies, and those living in areas with lower levels of education and higher levels of unemployment may have lower rates of COVID-19 vaccination, according...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer.1 Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
AI-Based Model for Nodal Metastasis Detection Using Whole-Slide Images in Bladder Cancer
In a Chinese study reported in The Lancet Oncology, Wu et al found that an artificial intelligence (AI)-based lymph node metastases diagnostic model using whole-slide images performed well in identifying lymph node metastases in patients with bladder cancer, as well as other cancers. Study Details...
Costs of Cancer in Adolescents and Young Adults in the United States
In an analysis by Deloitte Access Economics, commissioned by Teen Cancer America and reported in the Journal of Clinical Oncology, Parsons et al estimated the costs incurred after a cancer diagnosis by adolescents and young adults (AYAs) in the United States. Study Details The objective of the...
Magrolimab Plus Azacitidine in Higher-Risk Myelodysplastic Syndromes
In a phase Ib trial (5F9005) reported in the Journal of Clinical Oncology, David A. Sallman, MD, and colleagues found that the combination of magrolimab and azacitidine showed activity in previously untreated patients with intermediate- to very high–risk myelodysplastic syndromes (MDS). As stated...
Dan T. Vogl, MD, Comments on Follow-up of the UK NCRI Myeloma XI Trial
Dan T. Vogl, MD, Associate Professor of Medicine at the Hospital of the University of Pennsylvania and Director of the Abramson Cancer Center at the Perelman School of Medicine, Philadelphia, told The ASCO Post that the follow-up of the UK NCRI Myeloma XI trial confirms the importance of...
When Can You Stop Lenalidomide Maintenance in Myeloma?
A study aimed at determining the optimal duration of lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma has not answered that question, per se, but has yielded some hints that may inform future clinical trials. The follow-up analysis of the UK NCRI Myeloma XI...
Involving Hospitalists in Inpatient Cancer Care May Reduce Patient Stays, Oncologist Stress
Introducing hospitalists to cancer care comanagement may be associated with decreased lengths of hospital stays for patients, increased inpatient hospital capacity, and reduced stress levels among oncologists—all while maintaining high-quality inpatient care, according to a new study published by...
Delaying Treatment for Patients With Localized Prostate Cancer May Not Increase Mortality Risk, ProtecT Trial Shows
Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...
Large Study Finds Digital Breast Tomosynthesis May Be Superior to Digital Mammography for Breast Cancer Detection
In a study of over a million patients, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results were published by Conant et al in Radiology. Breast cancer screening with two-dimensional (2D) digital...
Health-Related Quality of Life in the KEYNOTE-826 Trial in Patients With Cervical Cancer
In an analysis from the phase III KEYNOTE-826 trial reported in The Lancet Oncology, Bradley J. Monk, MD, and colleagues found that the addition of pembrolizumab to chemotherapy with or without bevacizumab did not adversely affect health-related quality of life in patients with persistent,...
Regorafenib, Ipilimumab, and Nivolumab in Microsatellite-Stable Metastatic Colorectal Cancer
In a single-institution phase I trial reported in JAMA Oncology, Marwan Fakih, MD, and colleagues found that the combination of regorafenib, ipilimumab, and nivolumab showed evidence of activity in patients with microsatellite-stable metastatic colorectal cancer who did not have liver metastases....
Novel Urine Test May Play a Role in Bladder Cancer Prediction
Testing for genetic mutations in urine may help clinicians detect bladder cancer years before the disease shows clinical symptoms, according to new findings presented by Le Calvez-Kelm et al at the 2023 European Association of Urology Annual Congress (Abstract A0268). The researchers identified...
New Technique May Reduce Postoperative Complications in Prostate Cancer Surgery
Researchers have found that a novel technique used during prostate cancer surgery may reduce the risk of postoperative lymphocele by 50%, according to new findings presented by Neuberger et al at the 2023 European Association of Urology Annual Congress (Abstract A0656). The technique—involving the...
Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet, You et al found that hyperfractionated vs standard-fractionation intensity-modulated radiotherapy (IMRT) was associated with reduced late severe radiotherapy complications and improved overall survival in patients with locally advanced, recurrent ...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
Pelabresib Plus Ruxolitinib in Patients With Myelofibrosis and No Prior JAK Inhibitor Treatment
In the phase II MANIFEST trial, reported in the Journal of Clinical Oncology, John Mascarenhas, MD, and colleagues found that the combination of the bromodomain and extraterminal domain inhibitor pelabresib and ruxolitinib was active in patients with myelofibrosis who had received no prior Janus...
European OnCovid Registry Analysis of COVID-19 Sequelae During Omicron Phase vs Earlier Phases in Patients With Cancer
In an analysis from the European OnCovid registry reported in The Lancet Oncology, Alessio Cortellini, PhD, and colleagues found that rates of COVID-19 sequelae among patients with cancer were lower during the omicron phase of the pandemic vs the alpha-delta and prevaccination phases, consistent...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
PSMA-PET/CT May Help Improve Clinical Treatment of Prostate Cancer
A trial conducted at the University Hospital Bonn, Germany, has been testing the benefit of PSMA-PET/CT (prostate-specific membrane antigen–positron-emission tomography/computed tomography) to help target where to take biopsy samples, potentially improving the diagnosis of prostate cancer by giving ...
Impact of Tai Ji Quan or Strength Training vs Stretching in Preventing Falls in Postmenopausal Women Who Received Chemotherapy for Cancer
In the GET FIT study reported in the Journal of Clinical Oncology, Winters-Stone et al found no significant difference in incidence of falls with programs of tai ji quan (also known as tai chi) or strength training vs a stretching control group among postmenopausal women who had received...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
Study Reveals New Understanding of How Androgen Therapy Affects Breast Tissue
Molecular changes observed in the breast tissue of transgender men undergoing androgen therapy may signal the potential for also using the hormone to prevent or treat estrogen receptor–positive breast cancer. The findings were published by Raths et al in Cell Genomics. “These findings build upon...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
Miguel-Angel Perales, MD, Named 2023–2024 President of ASTCT
The American Society for Transplantation and Cellular Therapy (ASTCT) has chosen Miguel-Angel Perales, MD, as President of the Society in 2023–2024. Dr. Perales first served on the Board of Directors in 2017 and has been a member of ASTCT since 2001. He is Chief of the Adult Bone Marrow...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
'Don't Blame the Test'
“There are misconceptions about prostate cancer screening,” Karen Knudsen, MBA, PhD, said in an interview with The ASCO Post about newly published cancer statistics, including an increased incidence of prostate cancer, particularly advanced-stage disease. Dr. Knudsen is Chief Executive Officer of...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Novel Herbal Oncology Program for Management of Cancer Symptoms at an NCI-Designated Cancer Center
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, Guest Editor of the Integrative Oncology series, and Yen ...
Vanessa B. Sheppard, PhD, Named American Cancer Society Researcher of the Year
In recognition of her cancer research, Vanessa B. Sheppard, PhD, Associate Director for Community Outreach and Engagement and Health Disparities Research at Massey Cancer Center, has received the 2022 Researcher of the Year Award from the American Cancer Society (ACS). Dr. Sheppard, who was awarded ...
Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with...
Tucatinib With Trastuzumab in Previously Treated RAS Wild-Type HER2-Positive Advanced Colorectal Cancer
On January 19, 2023, tucatinib was grated accelerated approval for use in combination with trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Supporting Efficacy...
Unique Challenges of Cancer Care in India
In this installment of The ASCO Post’s Global Oncology, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Rajendra Toprani, MBBS, MS, MCh, Head of the Department of Head and Neck Surgical Oncology at HCG Cancer Centre, Ahmedabad, India. Dr. Toprani’s areas of interest include oral,...
Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UMPC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, Professor of Radiology at UMPC Magee-Womens Hospital, all of the University of Pittsburgh School of Medicine, have received ...
Expert Point of View: Anjali S. Advani, MD
Discussant of the February ASCO Plenary session, Anjali S. Advani, MD, Staff Physician in the Department of Hematologic Oncology and Blood Disorders and Director of the Inpatient Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, noted that the PhALLCON study is the only prospective...
PhALLCON Study: Ponatinib Superior to Imatinib in Combination With Chemotherapy in Newly Diagnosed, Ph-Positive ALL
Ponatinib appears to be a more effective tyrosine kinase inhibitor than imatinib in newly diagnosed, Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when combined with reduced-intensity chemotherapy, according to data presented during the ASCO Plenary Series: February 2023...
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight
On March 9, the U.S. Food and Drug Administration (FDA) published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities, and help interpreting...
Omission of Radiotherapy in Children and Adolescents With Early-Stage Classical Hodgkin Lymphoma With Adequate Response to OEPA Chemotherapy
As reported in The Lancet Oncology by Mauz-Körholz et al, children and adolescents with early-stage classical Hodgkin lymphoma enrolled in the EuroNet-PHL-C1 study who had an adequate response to an OEPA chemotherapy regimen (vincristine, etoposide, prednisone, and doxorubicin) and did not receive...
First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
Sacituzumab Govitecan-hziy in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 3, 2023, sacituzumab govitecan-hziy was approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization–negative) breast cancer who have received endocrine-based therapy and at...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
